Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded access to lenalidomide plus dexamethasone in previously treated multiple myeloma
2006-004532-73Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Time to disease progression. Started Nov 2006; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-004532-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004532-73.